Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis

This study has been terminated.
(Study was prematurely stopped due to slow recruitment after 17 of 32 anticipated patients were recruited.)
Information provided by (Responsible Party):
Dr. Falk Pharma GmbH
ClinicalTrials.gov Identifier:
First received: January 22, 2009
Last updated: January 26, 2012
Last verified: January 2012
To proof the superiority of an 8-week rectal treatment with once-daily 2 mg budesonide versus placebo for the prevention of acute radiation proctitis, and to evaluate the occurrence of chronic radiation proctitis 1 year after start of radiation therapy.

Condition Intervention Phase
Radiation Proctitis
Drug: budesonide
Drug: Placebo foam
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Randomised, Double-blind, Placebo-controlled, Multicentre, Comparative Phase II Pilot Study on the Efficacy and Tolerability of an 8-week Rectal Treatment With 2 mg Budesonide or Placebo for the Prevention of Acute Radiation Proctitis

Resource links provided by NLM:

Further study details as provided by Dr. Falk Pharma GmbH:

Primary Outcome Measures:
  • Proportion of patients developing radiation proctitis during treatment or need rescue medication [ Time Frame: within 8 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to occurrence of acute radiation proctitis [ Time Frame: During 8 weeks ] [ Designated as safety issue: No ]
  • Time to occurrence of chronic radiation proctitis [ Time Frame: Within 1 year ] [ Designated as safety issue: No ]
  • Adverse Events (AEs) [ Time Frame: During 8 weeks of treatment ] [ Designated as safety issue: Yes ]

Enrollment: 17
Study Start Date: September 2008
Study Completion Date: October 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
2mg rectal budesonide per day for 8 weeks
Drug: budesonide
One application of 2mg budesonide once daily for 8 weeks
Other Name: Budenofalk rectal foam
Placebo Comparator: 2
One application of placebo foam once daily for 8 weeks
Drug: Placebo foam
One application of placebo foam once daily for 8 weeks
Other Name: placebo


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent,
  • Men aged at least 18 years,
  • Patients with ECOG performance status <= 2 or Karnofsky Performance Status Scale >= 70%,
  • Estimated life expectancy more than 3 years,
  • Diagnosis of prostate carcinoma,
  • Indication for local RT in patients with prostatic cancer.

Exclusion Criteria:

  • Crohn's disease, indeterminate colitis, ulcerative colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis),
  • Severe or symptomatic ischaemic colitis at baseline,
  • Grade III internal haemorrhoids at baseline,
  • High risk patients needing extended radiation therapy,
  • Acute EORTC/RTOG lower GI toxicity score of >=1 at baseline,
  • Bacterial, amoebic, fungal, or viral infections of the gut,
  • Tuberculosis, hypertension, infection, diabetes mellitus (included familiarly predisposition), active peptic ulcer, osteoporosis, glaucoma, or cataract, if careful medical monitoring is not ensured,
  • Portal hypertension or liver cirrhosis,
  • Abnormal hepatic function (ALT, AST or AP > 2.5 x ULN),
  • Known intolerance/hypersensitivity/resistance to study drug or drugs of similar chemical structure or pharmacological profile, or to any of the other constituents of the study drug,
  • Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00828230

Klinik für Radioonkologie und Strahlentherapie - Klinikum Braunschweig
Braunschweig, Germany, 38114
Strahlentherapie, St. Vincentius-Kliniken gAG
Karlsruhe, Germany, 76135
Strahlentherapie, Klinikum Mutterhaus der Borromäerinnen
Trier, Germany, 54290
Sponsors and Collaborators
Dr. Falk Pharma GmbH
Study Director: Ralph Mueller, Dr Dr. Falk Pharma GmbH
  More Information

Responsible Party: Dr. Falk Pharma GmbH
ClinicalTrials.gov Identifier: NCT00828230     History of Changes
Other Study ID Numbers: BUF-17/RAP  EudraCT No.: 2007-002082-13 
Study First Received: January 22, 2009
Last Updated: January 26, 2012
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Dr. Falk Pharma GmbH:
acute radiation proctitis
late radiation proctitis
Prevention of acute radiation proctitis
Prevention of late radiation proctitis

Additional relevant MeSH terms:
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Autonomic Agents
Bronchodilator Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 02, 2016